Bleximenib Shows Promise with Venetoclax and Azacitidine in AML
Bleximenib Shows Promise in AML When Combined with Venetoclax and Azacitidine, According to Johnson & Johnson’s Phase 1b Data Presented at EHA 2025 Johnson & Johnson today presented new and…
First Patient Dosed in Phase 3 REVEAL Trial of ION582 for Angelman Syndrome
Ionis Begins Pivotal Phase 3 REVEAL Study of ION582 in Angelman Syndrome, Dosing First Patient in Global Trial Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) has announced the dosing of the first…
Parliamentarians Gather for Annual World Health Assembly
Global Parliamentarians Take the Stage at WHA78: A New Chapter in Health Governance The Seventy-eighth World Health Assembly (WHA78), held in Geneva in 2025, emerged as a landmark moment in…
FDA Approves Tablet Form of BeOne’s BRUKINSA® for All Indications
FDA Approves Tablet Formulation of BeOne’s BRUKINSA® for All Approved Indications, Offering Greater Convenience for Patients with B-cell Cancers BeOne Medicines Ltd. a global oncology-focused biopharmaceutical company, has received a…
argenx Unveils Positive Efgartigimod Phase 2 Data in Myositis and Sjogren’s at EULAR 2025
argenx Unveils Positive Phase 2 Results for Efgartigimod in Myositis and Sjogren’s Disease at EULAR 2025 argenx SE a global immunology company dedicated to advancing treatments for severe autoimmune diseases,…
Bayer, Broad Institute Extend Cardiovascular Drug Research Pact
Bayer and Broad Institute Extend Landmark Collaboration to Advance Cardiovascular Genomics and Precision Medicine In a bold continuation of a decade-long scientific alliance, Bayer and the Broad Institute of MIT…
Dapirolizumab Pegol Phase 3 Data Shows SLE Fatigue and Disease Activity Improvement at EULAR
Dapirolizumab Pegol Demonstrates Promise in Phase 3 SLE Trial, Showing Improvements in Fatigue and Disease Activity at EULAR 2025 UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) presented comprehensive…
Bristol Myers Squibb Unveils Positive Phase 3 Data for Sotyktu in Psoriatic Arthritis
Bristol Myers Squibb Unveils Compelling Late-Breaking Phase 3 Data Highlighting the Efficacy of Sotyktu (Deucravacitinib) in Treating Psoriatic Arthritis Bristol Myers Squibb has announced new late-breaking clinical data from the…
FDA Approves Expanded Use of AbbVie’s MAVYRET for Acute Hepatitis C
FDA Expands Approval of AbbVie’s MAVYRET® as First and Only 8-Week Treatment for Acute Hepatitis C in Adults and Children Aged 3 and Above AbbVie has received a significant regulatory…
TransCon CNP Shows Enhanced Benefits in Children with Achondroplasia at Week 26 of COACH Trial
Ascendis Pharma Reports Promising Week 26 Results from COACH Trial: TransCon hGH Enhances TransCon CNP Benefits in Children with Achondroplasia Ascendis Pharma A/S, a global biopharmaceutical company focused on developing…
Fourth IHR Emergency Meeting on 2024 Mpox Surge – Temporary Recommendations
WHO Maintains Global Health Emergency Status for Mpox Amid 2024 Surge, Issues Strengthened Recommendations In response to the continuing resurgence of mpox across several regions in 2024, the World Health…
Jazz Pharma Unveils Late-Stage Xywav® Data in Narcolepsy at SLEEP 2025
Jazz Pharmaceuticals Showcases Promising Phase 4 Results for Xywav® in Narcolepsy at SLEEP 2025, Underscoring Cardiovascular and Symptom Management Benefits Jazz Pharmaceuticals plc presented compelling new late-breaking data at the…